The study, led by Cycuria’s scientific founder, Prof. Dr. Philipp Jost , a clinician-scientist, and his research team, describes a natural tumor-suppressing mechanism mediated by lymphotoxin alpha (LTA).
Read the full press release here: Cycuria Press Release on STM Publication_26112025
Editor’s summary Relapse of acute myeloid leukemia (AML) is driven by populations of leukemic stem or progenitor cells (LSCs), which are resistant to chemotherapy. Here,
Join our CEO as he presents Cycuria Therapeutics‘ latest advancements in oncology innovation at the upcoming BIO-Europe conference in Vienna . 📍 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗩𝗶𝗲𝗻𝗻𝗮 🗓️
🧬 𝗣𝗮𝗻𝗲𝗹: “Science With Purpose – Bold Biotech in Uncertain Times” 📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟯–𝟮𝟰, 𝟮𝟬𝟮𝟱 📍 Great value for money This session will bring together
We’re pleased to share an exclusive interview with our CEO featured by ABA – INVEST in AUSTRIA ! In this article, we talk about Cycuria
At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.